Scientists discover how to restore eyesight without laser surgery

Scientists are on the verge of developing a less invasive and more affordable, incision-free method to treat vision problems.

Chemists in California stumbled upon the idea that vision issues could be addressed chemically, without the need for lasers.

The team used a tiny electric current to lower the cornea’s pH, making it more acidic. This loosened its collagen structure and made it moldable.

A platinum lens designed as an ideal shape was placed over the cornea. As the tissue softened, it conformed to the lens’s curve. Restoring the pH locked it into place.

They tested the power of manipulating pH and fitting the plate in rabbit eyeballs in saline solution. The eyes consistently conformed to the plate, maintaining their shape 12 out of 12 times, and even showed signs of eliminating nearsightedness in two of them.

In lab tests, the team used a saline-soaked rabbit eyeball to mimic conditions in real human eyes, and applied their pH-shifting technique. All 12 eyeballs successfully conformed to the desired shape of the template and, in 10 cases, deliberately modeled to mimic nearsightedness, the corneas adjusted to correct vision.

Americans often treat vision problems, such as nearsightedness, farsightedness, and astigmatism, without surgery. Roughly 167 million people wear prescription eyeglasses, while 45 million use contact lenses.

A healthy eye has a white outer part (sclera), clear front surface (cornea), and properly functioning internal structures that focus light perfectly on the retina.

When the cornea is correctly curved, light bends precisely onto the retina for sharp vision.

In impaired vision, such as nearsightedness, the cornea is too steep or flat, causing light to focus in front of or behind the retina instead.

Reshaping the cornea through LASIK adjusts the cornea’s curvature, which allows light to hit the retina properly and restore clear focus.

LASIK is generally for those who want to do away with their eyeglasses and contact lenses.

While the laser surgery is overall safe, it is not risk-free. Common short-term side effects include dry eyes, glare, especially at night, and rare complications like still needing glasses, healing issues with the corneal flap or corneal weakening over time, leading to lasting vision impairment.

Most issues resolve, but some may need enhancement surgery or have lasting effects. Not everyone qualifies. Surgeons screen for thin corneas or other risk factors first.

Now, researchers are exploring a way to reshape the cornea without having to make any incisions through a process known as electromechanical reshaping (EMR).

‘The whole effect was discovered by accident,’ said Brian Wong, a professor and surgeon at the University of California, Irvine.

‘I was looking at living tissues as moldable materials and discovered this whole process of chemical modification.’

Collagen-rich tissues, including corneas, rely on magnetic-like attractions between charged particles to hold their shape.

Introducing a tiny electric current lowers the pH of the gel-like fluid surrounding its collagen fibers, turning rigid tissue temporarily soft.

While the rabbit eye tissue was soft, Dr Wong and his partner, Dr Michael Hill, a professor of chemistry at Occidental College, applied the perfectly-shaped platinum plate to mold the cornea into a new shape. It did so in about a minute.

When they restored pH, those attractions tightened, freezing the tissue in its new form.

The work is still in its early stages. It is expected to begin a long process of detailed and precise studies in living animals, not just eyeballs in saline.

The team will next explore how well EMR can treat common vision issues like nearsightedness, farsightedness and astigmatism.

Dr Hill said: ‘There’s a long road between what we’ve done and the clinic.

‘But, if we get there, this technique is widely applicable, vastly cheaper and potentially even reversible.’

The team’s findings were presented at the fall meeting of the American Chemical Society this week.

Click here to read full article on the Daily Mail website.

Electric Bursts Reshape the Cornea to Improve Eyesight Without LASIK

A noninvasive approach to correcting misshapen eyeballs could expand treatment options for people with vision problems where LASIK is out of reach.

Written by Shelby Bradford, PhD

Corrective vision surgeries, like LASIK, improve people’s quality of life. However, this procedure relies upon using a laser to remove layers of tissue from the cornea, increasing costs and recovery times.

A new method to reshape the proteins in this eye tissue could provide an alternative approach to improve people’s eyesight. Researchers used electricity and a shaped lens to remodel the corneas of rabbit eyes ex vivo. They presented the technique at the fall meeting of the American Chemical Society.

The cornea is the outermost layer of the eye, providing overall protection to it. Collagen fibers in the cornea maintain the tissue’s structure and strength.1 Brian Wong, a head and neck surgeon at the University of California, Irvine, was interested in developing less invasive means to modify this collagen in the eye tissues. He thought that if he could disrupt the collagen structure, then he could remold it like plastic. Using electricity, he and his team successfully reshaped resected rabbit ears and eyes, although the eye tissue became opaque.

To explore this process further, the team recruited inorganic chemist and electrochemist Michael Hill at Occidental College. After establishing that their electromechanical reshaping method reformed collagen structure by altering the pH of the tissue, the teams turned to the biggest challenge: reshaping the cornea without turning it opaque.

According to Hill, the first objective was to determine the pH at which the cornea softened and also the point at which it became clouded. He and his team found that the collagen turned malleable at a pH of two, while opacity set it at a pH of about 1.5. “So, we have this tiny, narrow, little window where we have to get the pH profile in order to reshape it, but not make it cloudy,” Hill said.

To adjust the pH to reshape the tissue without damaging it, Hill explained that the difficulty lay in being able to reach a pH of two across the whole cornea before the area nearest the electrode plate dropped to the damage-inducing 1.5.

The solution, Hill explained in his talk, was to deliver the electrical dose in bursts. Using modeling, they determined how frequently they needed to deliver a burst and how long they needed to wait for the pH change to diffuse through the tissue.

Currently, the researchers are developing a live animal model to test their new technique, since Hill said an outstanding question is how long these changes last in the tissue. “If it turns out that we can reshape the cornea, as we know we can, but then in a couple of days, it’s back to its original place, then it’s of really little practical use,” he explained.

If successful, the procedure offers an alternative corneal corrective approach for instances where LASIK is not an available option, such as when a lot of tissue would need to be removed. Additionally, Hill said that the findings offer a new platform to manipulate tissues in a non-invasive approach.

“It’s just a paradigm shift in that, instead of having this tissue and carving it and suturing it and mechanically manipulating it, we’re thinking about it in terms of the material, and how can we change the mechanical properties of it, from a chemical perspective, to remold it and repurpose it,” Hill said.

Meek KM. Corneal collagen—its role in maintaining corneal shape and transparencyBiophys Rev. 2009;1:83-93.

Click here to read full article on The Scientist website.

LASIK alternative in the works

Professor Howard Lee receives Proof of Product award from UCI Beall Applied Innovation

The award will support Lee’s research into high power hollow optical fibers used in geothermal drilling.
Thursday, August 14, 2025 | Lucas Van Wyk Joel | UC Irvine Physical Sciences Communications
Professor Howard Lee of the UC Irvine Department of Physics & Astronomy recently received a Proof of Product (PoP) award from UCI Beall Applied Innovation – an award that helps researchers like Lee move their discoveries from the lab to the commercial marketplace. The award, which will give Lee and his group $60,000 in research funding, will support his group’s research into designing different type of hollow core optical fibers with applications to geothermal drilling and high-power laser technologies as well as provide guidance on enhancing the appeal of the technology to industry stakeholders and investors. “The PoP grant from UCI BAI allows us to explore this promising idea and access its potential for practical technologies,” said Lee, who’s also part of an entrepreneurial training program offered by the National Science Foundation called I-Corp. “Participation in the regional I-Corp program and discussion with BAI staff will further strengthen our understanding of this important market segment.”
Click here to read full news brief on the UC Irvine School of Physical Sciences website.

UC Irvine Institute Faculty Receive Proof of Product Grants to Advance Breakthrough Discoveries

Two Beckman Laser Institute & Medical Clinic researchers awarded funding to accelerate market-ready innovations

Two faculty members from UC Irvine’s Beckman Laser Institute & Medical Clinic have been selected for spring 2025 Proof of Product (PoP) grants from UC Irvine Beall Applied Innovation, bringing their groundbreaking research closer to real-world applications.

Bridging Research and Market Impact

UC Irvine Beall Applied Innovation’s PoP Grants program identifies researchers with early-stage projects that show exceptional commercial potential. The program provides up to $100,000 in critical funding to help Principal Investigators (PIs) navigate pivotal development phases, including customer discovery and market validation, feasibility studies and technical assessments, prototype development and testing and industry partnership development

This strategic investment accelerates the pathway from laboratory discovery to market-ready solutions that can measurably improve lives.

Spring 2025 Institute Awardees

Medical Devices Track
Dr. Brian Wong, School of Medicine
Project: Electrochemical clearing of the cornea post-chemical injury

General Track
Dr. Howard Lee, School of Physical Sciences
Project: Hollow core optical fiber bundle for high-power laser delivery in geothermal drilling*

These diverse projects demonstrate the university’s commitment to translating cutting-edge research into practical solutions across multiple industries, from medical treatment to sustainable energy.

Click here for more information about UC Irvine Beall Applied Innovation, the PoP Grant Program, and the complete list of awardees.

 

Botvinick’s BEAMS Lab joins the AIMBE Congressional Tour of the NIBIB

On July 18, 2025, Dr. Elliot Botvinck’s Bio-Engineering of Advanced Mechanical Systems (BEAMS) laboratory was selected by the American Institute of Medical and Biological Engineering (AIMBE) to participate in a technology demonstration during the Congressional Tour of the National Institute of Biomedical Imaging and Bioengineering (NIBIB).  The event welcomed more than 56 congressional staff members to the NIH, where they observed cutting-edge technology demonstrations presented by NIBIB grantees. Staff members also toured laboratories of NIBIB intramural researchers to learn about groundbreaking biomedical research advancements supported by the Institute.

The BEAMS laboratory demonstration was led by Senior Scientist Dr. John Weidling alongside PhD students Toni Wilkinson and Emma Caudill.   The team presented their LifeStrip multi-analyte continuous sensor through a comprehensive large-scale demonstration of its operation, complimented by video microscopy to showcase the device’s remarkably compact size.

During the presentation, the team emphasized the multidisciplinary expertise essential for pioneering this technology and accelerating research efforts toward clinical studies.  They highlighted how each expert represented in their collaborative network (featured in the outer ring of the diagram) had completed more than 10 years of rigorous education and training, including earning PhD degrees.  These achievements have traditionally been supported by NIH and NIBIB funding.  The presentation illustrated how advancements across individual scientific fields (featured in the inner ring of the diagram) converged to develop this technology and demonstrated the project’s broader impact on the work of other investigators and companies.  The team also addressed the technology’s potential to create U.S. manufacturing jobs, reduce healthcare costs, and enhance patient care outcomes.

The BEAMS laboratory joined demonstrations from other prestigious institutions during the AIMBE Congressional Tour, including Carnegie Mellon University, The University of Chicago, and Boston University; as well as presentations from NIBIB’s Advanced Imaging and Microscopy (AIM) resource and the Center for Biomedical Engineering Technology Acceleration (BETA Center).

Click here to learn more about the AIMBE Congressional Tour om the NIBIB website.

Click here to visit the Bio-Engineering of Advanced Mechanical Systems (BEAMS) laboratory website.

Shcherbakov recognized as Optica 2025 Senior Member

Dr. Maxim Shcherbakov, Assistant Professor, Electrical Engineering and Computer Science, has been recognized as a 2025 Senior Member of Optica.

Dr. Shcherbakov’s research merges physics and cutting-edge nanotechnology to revolutionize photonic devices. He uses theoretical and experimental methods to conceive next-generation light-based components for use in imagers, augmented reality (AR)/virtual reality (VR) technology, telecommunications, and quantum computing.

The Optica designation of OSA Senior Member is a recognition of researchers who have demonstrated significant experience and accomplishments in their professional careers. This honor distinguishes Dr. Shcherbakov as a leader and innovator in the optics and photonics community. Congratulations to Dr. Shcherbakov for this prestigious honor, acknowledging his significant contributions to the field of optics and photonics.

Click here for a full list of 2025 OSA Senior Members.

UC Irvine researchers discover drug compounds to block blood-vessel branching in skin and tumors

New angiogenesis inhibitors have potential to treat cancer and skin diseases

Irvine, Calif. — A research team led by scientists at the University of California, Irvine has discovered new drug compounds that can block blood-vessel branching in both skin tissue and tumors.

The compounds work by blocking proteins needed to form new blood vessels, a process known as angiogenesis, the researchers report in the study published today in the journal iScience. A team of scientists at the Italian Institute of Technology also contributed to the research.

Anti-angiogenesis drugs have long been used to block tumor growth in many types of cancer. Yet they are largely ineffective at treating melanoma, the most aggressive skin cancer. Most skin tumors need to develop a blood supply to grow beyond 1 millimeter in depth.

The researchers focused on compounds with the potential to disrupt two molecular switches thought to control blood-vessel branching in the skin, CDC42 and RhoJ, said corresponding author and UCI Health dermatologist Anand Ganesan, MD, PhD.

The study measured the effects of the drugs discovered by the Ganesan research team — called CDC42-effector interaction inhibitors — on blood-vessel branching. They compared these CDC42 interaction inhibitors, which can block signals generated by the RhoJ molecular switch, with existing drugs that prevent the CDC42 molecular switch from turning on. They demonstrated that blocking RhoJ, but not CDC42, inhibited blood-vessel branching in skin, said Ganesan, a UC Irvine professor of dermatology and biological chemistry whose lab led the study.

“Importantly, this anti-vascular effect was not limited to skin; the class of drugs also blocked melanoma tumor vascularization and inhibited tumor growth,” he said. “Taken together, the CDC42-effector interaction inhibitors work as selective anti-vascular agents that can be used to treat both cancer and skin disease.”

While further study is needed to decipher exactly how vessel-branching in skin is regulated, Ganesan said the team is now focused on understanding whether CDC42 interaction inhibitors could be used to treat skin conditions characterized by a proliferation of blood vessels, including rosacea and other inherited vascular disorders.

The UC Irvine research team included first author Linh M. Vuong, PhD; Stephanie Hachey, PhD; Jessica Shiu, MD, PhD; Danny F. Xie; Noel Salvador, PhD; Rachel Pham; Vance Ku; Swara D. Limbekar; Terry Nguyen; Bernard Choi, PhD, and Christopher C.W. Hughes, PhD, a UC Irvine Chancellor’s Professor of molecular biology and biochemistry. A team of researchers led by Marco de Vivo at the Italian Institute of Technology in Genoa provided critically important molecular modeling and translational pharmacology expertise.

The research was funded by grants from the National Cancer Institute, the Italian Association for Cancer Research, the National Institute for Arthritis and Musculoskeletal Disease, and the Clinical Innovation Incubator, a new UC Irvine Department of Dermatology program that provides pilot funding to support the development of innovative solutions for clinical problems.

Anand Ganesan, MD, PhD, a UC Irvine dermatologist, is the author or co-author of more than 50 peer-reviewed publications. His research focuses on understanding how signaling between different skin cell types drives the formation of cancer and skin disease. His goal is to develop new therapies to treat melanoma and other skin diseases. Ganesan serves as co-director of Biotechnology, Imaging and Drug Development and co-director for Molecular Diagnostics and Therapeutics at the UCI Health Chao Family Comprehensive Cancer Center. He is also associate dean for Physician-Scientist Development at the UC Irvine School of Medicine and vice chair for research for its Department of Dermatology.

Learn more about UCI Health Dermatology Services.

Click here to read full article on the UCI Health website.

 

 

 

Lasers for Pediatric Skin Conditions Require a Different Approach Than in Adults

By Richard Mark Kirkner, Medscape

Children can benefit from a variety of dermatologic laser procedures, from hair removal to treatment of scars and vascular anomalies. However, the data on the safety and effectiveness of lasers for treating skin conditions in pediatric patients are lacking, as are clinical guidelines.

Lasers have been widely used in pediatric dermatology, with the earliest reports of laser treatment of port-wine stains going back 30 years or more. The steady evolution of devices has improved clinical results, but the use of lasers in children for dermatologic conditions carries unique challenges, pediatric dermatologists who specialize in laser treatments have reported.

A multitude of indications for ablative fractional lasers (AFLs) for pediatric patients exist. However, “performing laser surgery on kids tends to be a very different experience than working with adult patients,” Andrew C. Krakowski, MD, network chair of dermatology at St. Luke’s University Health Network in Easton, Pennsylvania, told Medscape Medical News. “First off, adult patients want to be there, usually to have something being made to look better. Kids, on the other hand, want to be anywhere other than the doctor’s office.”

Lasers can be useful for patients of all ages, “from newborns to people over 100 years old, depending on what you’re trying to treat,” Kristen M. Kelly, MD, professor and chair of dermatology at UC Irvine School of Medicine, told Medscape Medical News. “Just like any therapeutic modality, you want to make sure that you know how to use it, that you’re using it for the correct indications, you’re using it in the correct way for that particular indication.”

Indications for Lasers in Pediatric Dermatology

Pediatric patients can undergo laser procedures for many of the same indications as adults, including hair removal. Anna Yasmine Kirkorian, MD, chief of dermatology at Children’s National Hospital, Washington, DC, and colleagues reviewed the ethical and clinical considerations of lasers and other hair removal modalities in pediatric patients in a 2024 review. “All methods of hair removal appear to be safe and generally well tolerated in children, and there are no age restrictions to any modality,” Kirkorian and her coauthors wrote. Regarding lasers specifically, they added, “In the pediatric population, lasers have the most extensive data supporting their use for hair removal, and their safety profile in treating other dermatologic conditions adds to the existing body of evidence.”

AFL can be used for a host of scarring indications in pediatric patients, including hypertrophic scarring, keloid scarring, acne scarring, and surgical scarring. At the Society for Pediatric Dermatology annual meeting held the day before the American Academy of Dermatology meeting in March, Krakowski said the treatment of self-cutting scars is another indication.

“A big focus of mine is treating kids’ scars, not just the appearance of scars but, perhaps even more importantly, any deficit in function the scar may be causing,” Krakowski told Medscape Medical News.

Other pediatric indications Krakowski enumerated include collagen nodules and contracture, repigmentation of pulse dye laser hypopigmentation, porokeratotic eccrine ostial and dermal duct nevus, Dowling-Degos disease, angiofibromas in tuberous sclerosis, recessive dystrophic epidermolysis bullosa, Goltz syndrome, and infantile hemangiomas and birthmarks.

Psychosocial Issues in Children

“Scars can also be associated with posttraumatic stress disorder and depression,” Krakowski said. Burn scars are a typical example of the latter. And disfiguring scars can also be associated with increased anxiety and feelings of social isolation in adolescents and teenagers.

“These scar-related comorbidities are often under-investigated and underreported, so you really have to make the deliberate point to ask your patients and then be prepared to address what they share,” he said.

Children with chronic skin conditions deal with a host of psychosocial issues, such as bullying and stigmatization, different from those that adults deal with, a multisite cross-sectional study of 1671 children published last year in JAMA Dermatology reported.

The study concluded that this is an area that requires further study and one that dermatologists need to take more seriously. While skin disorders “are often regarded as less serious” than other groups of diseases, “a child or adolescent with a chronic skin disorder risks becoming the target for bullying, alienation, and feelings of reduced self-worth, leading to stigma,” the authors wrote.

“There are both physical and emotional scars,” Kelly said. “Sometimes, that’s something that people need an opportunity to be able to deal with.” In some cases, other resources, such as counseling or group therapy, may be in order, she said.

Informed Consent for Pediatric Patients

Obtaining informed consent for a dermatologic laser procedure for a child is far different from the process for adults, Kirkorian told Medscape Medical News. “Children cannot consent to procedures, but as often as is possible, they should be able to assent,” she said. The dermatologist must be able to explain the procedure to the child in an age-appropriate manner.

“For procedures, such as laser hair removal, which are elective and not medically necessary, the child should both want to participate in the procedure and be able to comply with safety requirements,” such as having the ability to wear eye protection and stay still during the procedure, she said.

Parents play an integral role in the informed consent process because they are the ones ultimately giving the informed consent for their child, Kirkorian said. But the child must also cooperate. “It’s important that we do not force children to undergo procedures that are not medically necessary or the only option if they are unwilling participants,” she said.

Two examples Kirkorian offered where the child’s cooperation is vital are cryotherapy for the treatment of verruca and intralesional steroid injections for the treatment of alopecia areata. She only performs these procedures on children if they “are willing and able to participate because these procedures can be painful and do not lead to resolution of the condition in all cases,” she said. “If a child cannot or will not participate with such procedures, then alternative medical treatments would be indicated.”

Medically necessary procedures, such as biopsy of a changing nevus, require a different approach, she said. “If a child cannot comply, then we consider a sedated procedure as an alternative,” Kirkorian said.

Informing parents and children of procedures requires different approaches for each, Kelly said. “Obviously, the language you might use for the parents and the children could be somewhat different because certainly, you want everyone to understand.”

In addition, “you want to work with the parents to find the best way to approach the information with the child,” she added. “You want them to be informed. You also don’t want to create unnecessary fear, and so you need to find the right approach to let them know what will be happening but not scare them.”

Pain Management in Children

Children also have different pain management needs. “Obviously, it’s not a totally painless procedure,” Lisa Arkin, MD, director of Pediatric Dermatology and co-director of the Birthmarks and Vascular Anomalies Program at the University of Wisconsin School of Medicine and Public Health in Madison, Wisconsin, said of laser ablation. “Most kids of an appropriately selected age and maturity can tolerate these procedures in the office.”

Here, the dermatologist may need to take a nuanced approach based on the type of injury or condition being treated, she said. “There’s always sort of a select patient population, particularly the kids who’ve had extensive burns, where there’s just too much trauma, and you just need to leverage general anesthesia to keep them comfortable.”

In children, the same principles apply as in adults: mitigating anxiety, pain, and fear, Arkin said. Techniques include topical anesthetic cream, cooling of the epidermis, and use of the Buzzy handheld device that combines a reusable ice pack and vibration near the treatment area.

“Control is a big thing for kids,” Arkin said. “They want to know how much it’s going to hurt and how many pulses it will take so that they can mentally wrap their head around expectations.”

Another strategy in small children that Kirkorian has found useful is having the parent hold the child during the laser treatment. “There are many positions or embraces that can be taught, especially by collaborating with child-life teams,” she said. “The parent’s job is to provide comfort, not to ‘hold the child down.’”

Besides topical anesthetics, vibratory devices, and cold sprays, other approaches include distraction with videos, music, or virtual reality, Kirkorian said.

“Lastly, dermatologists who perform procedures on children should feel very comfortable doing so and be able to perform the procedures quickly and effectively on a moving patient,” she added. Otherwise, the child should be referred to a board-certified pediatric dermatologist.

Managing Expectations

Preparing parents and children for the eventual outcome also requires some skill and nuance. “Dermatologists should explain the procedure plan in detail with parents in advance of the procedure while being mindful that this discussion might be best performed without the child present in case it will increase the child’s anxiety if it is a small child,” Kirkorian said.

“For older children or adolescents, it’s important to include them in the discussion because they cannot be ‘held down’ or restrained safely, so they need to be able to understand and assent,” she added.

Kelly gave an example of how that conversation can go with a child. “If I’m treating a scar — and I would say the same thing to adults — I never promise that I’m going to completely remove the scar,” she said. “I’m not going to be able to make it go away like it had never happened, but we can dramatically improve it.”

A Word About Teenagers

In Krakowski’s experience, “teenagers are awesome” and have often been the most motivated of patients “because they want nothing more than to fit in with their peers,” whereas adults “tend to want to stand out from the people around them.”

However, teenagers can also present unique challenges compared with younger children, he said.

“The trouble with teenagers, though, is that they are old enough and strong enough to be able to get off the exam table and walk out of the procedure room,” Krakowski said. “You can be halfway through a procedure, and if they decide they are finished, there is not much you can do about it.”

His advice: Plan ahead so that the treatment can be completed. For example, to treat atrophic scars from chronically inflamed acne, which is the most common condition he treats with lasers in teenagers, he’s switched from AFL to a fractional nonablative device because patients tolerate it better. Referring to AFL, he said, “I know this device hurts and is associated with significant downtime.”

With the nonablative device, “I can finish the treatments, and I know the patients will notice some significant improvement by the end of our third or fourth treatment session,” Krakowski said.

That, he said, improves the chances that these potentially difficult pediatric patients will complete their treatment.

Click here to read full article on Medscape.

Moles can become melanomas through nongenetic transitions, UC Irvine study shows

Irvine, Calif., June 26, 2025 — Researchers at the University of California, Irvine exploring the genesis of melanoma have identified a cell type in animal and human models that can initiate tumors in the absence of other genetic mutations.

These cells, which resemble neural crest stem cells, were found to be present in human and mouse melanomas, as well as in normal skin, the researchers report in a study published today in the journal Nature Communications. Single-cell transcriptomics and advanced bioinformatics approaches revealed that these cells could act as “precursors of malignant cells,” a finding that has significant implications for developing strategies to detect melanoma early or even prevent melanoma from forming.

“We show that an initial mutation, known to generate either a normal mole or a tumor, need not be followed by a second mutation to change into a melanoma tumor,” said Anand Ganesan, MD, PhD, a UC Irvine professor of dermatology and biological chemistry and corresponding author of the study.

“This opens up the possibility of reverting the tumor cell to back into a normal cell if indeed the event that is causing it is not permanent, like a mutation,” added the UCI Health dermatologist and skin cancer specialist. “It also opens up the possibility that one could design a therapy to stop this cellular transition as a way to prevent melanoma.”

Melanoma, which is expected to cause more than 8,000 U.S. deaths in 2025, is a type of cancer that arises in the skin’s pigment-making cells. Called melanocytes, these cells can form a pigmented lesion on the skin called a “mole” and also known as a nevus. Most moles are benign, but those that become melanomas can spread rapidly to other organs throughout the body.

Difficult to diagnose

About 90% of tumors detected early can be cured with surgery, but they can be difficult to diagnose in an initial biopsy. Tracking the transition of the neural crest-like cells could help better identify melanoma in its beginning stages for removal and a cure.

What triggers the change from mole to tumor has been the subject of study for years. Most melanomas are thought to result from exposure to harmful ultraviolet rays. However, other melanomas found in hidden parts of the body not exposed to the sun are difficult to detect let alone prevent.

“Cancer initiation begins with a mutation, but unraveling the sequence and number of mutations required to generate tumors has been challenging,” said Ganesan, a physician-scientist whose previous work has included developing new compounds with the potential to slow the grow of skin cancers. He also serves as co-director for Molecular Diagnostics and Therapeutics at the UCI Health Chao Family Comprehensive Cancer Center.

The research team led by Hui Xiao, PhD, a former graduate student in Ganesan’s lab, conducted In-depth genetic studies of mouse models with mutations of the cell growth-regulating gene BRAF. While the BRAF mutation induced rare melanomas in albino mice, it induced only normal moles in black mice. Notably, consistent mutations were not found in the tumors that arose in albino mice, indicating that additional mutations were not required to generate tumors.

Potential marker for malignancy

“The detection of the cells that can form tumors in biopsies may represent a clinically useful marker of malignant potential as it appears that they are observed in melanomas arising in both mice and humans,” the study said.

“If cancer formation is strictly dependent on the accumulation of genetic mutations, then the only way to prevent cancer would involve preventing the accumulation of additional mutations,” Ganesan added.

“On the other hand, if tumor initiation involves a combination of a mutation and non-genetic events, preventing nongenetic events would be a method to prevent cancer formation.  Thus, while wearing sunscreen to prevent mutations is still important in preventing melanomas and other cancers, there may be other therapies we could devise that could prevent normal melanocytes from transitioning into melanoma cells.”

The work required close collaboration between Ganesan and Arthur D. Lander, MD, PhD, an expert in computational biology and the Donald Bren Professor of Developmental Biology, as well as Qing Nie, PhD, an expert in single-cell bioinformatics and the Chancellor’s Professor of Mathematics. The research team also included Jessica Shiu, MD, PhD; Chi-Fen Chen, MS; Jie Wu, PhD; Peijie Zhou, PhD; Sahil S. Telang; Rolando Ruiz-Vega, PhD; and Robert A. Edwards, MD, PhD.

The study was funded by grants from the National Cancer Institute and the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Anand Ganesan, MD, PhD, a UC Irvine physician-scientist specializing in pigmentary disorders and skin cancer, is the author or co-author of more than 50 peer-reviewed publications. His research focuses on understanding how pigment cells function in the skin; how they give skin its color; how they are lost in vitiligo, and how they can transform into melanoma. His goal is to develop new therapies to treat melanoma and pigmentary disorders. Ganesan serves as co-director for Biotechnology, Imaging and Drug Development and co-director for Molecular Diagnostics and Therapeutics at the UCI Health Chao Family Comprehensive Cancer Center. He is also associate dean for Physician-Scientist Development at the UC Irvine School of Medicine and vice chair for research for the medical school’s Department of Dermatology.

The UCI Health Chao Family Comprehensive Cancer Center is one of only 57 National Cancer Institute-designated U.S. comprehensive cancer centers and the only one based in Orange County, the sixth most populous county in the nation. A research powerhouse, the cancer center brings together basic and translational scientists with clinician investigators to drive discoveries through the pipeline into the clinical arena. The center treats more patients with cancer — and more complex cases — than any other healthcare provider in the region, with more than 80,000 outpatient visits and 65,000 infusion treatments annually at practice sites in Orange, Irvine, Yorba Linda, Newport Beach, Costa Mesa and Laguna Hills. The center also offers more than 500 clinical trials, including the region’s largest portfolio of early-phase and investigator-initiated trials. It has the only adult bone marrow transplant program in Orange County, performing more than 100 transplants a year and enabling critically ill patients to receive life-saving care close to home. It is also one of the few U.S. programs to provide transplants for debilitating autoimmune diseases such as multiple sclerosis. With the opening of its second clinical hub in Irvine in July 2024, the cancer center has tripled its space to treat cancer patients and conduct novel studies aimed at bringing an end to cancer.

UCI Health, one of California’s largest academic health systems, is the clinical enterprise of the University of California, Irvine. The 1,317-bed system comprises its main campus UCI Medical Center, its flagship hospital in Orange, Calif., the UCI Health — Irvine medical campus, four hospitals and affiliated physicians of the UCI Health Community Network in Orange and Los Angeles counties and a network of ambulatory care centers across the region. UCI Medical Center provides tertiary and quaternary care and is home to the only Orange County-based National Cancer Institute-designated comprehensive cancer centerhigh-risk perinatal/neonatal program and American College of Surgeons-verified Level I adult and Level II pediatric trauma center, gold level 1 geriatric emergency department and regional burn center. Powered by UC Irvine, UCI Health serves nearly 4 million people in Orange County, western Riverside County and southeast Los Angeles County. Follow us on FacebookInstagramLinkedIn and X (formerly Twitter).

Find on-demand care at UCI Health using our On Demand Care Finder ›

Click here to read full article on the UCI Health website.